Fig. 1.

Progression-free survival (PFS) per central assessment (A) and overall survival (B). Tumor assessments that were taken after initiation of any non–AMG 102 antitumor therapy, tumor resection, or first tumor progression were excluded from PFS. All deaths were included. PFS was defined as the time in weeks from the first dose of AMG 102 to first progression by Macdonald criteria or death from any cause, whichever occurred first. Patients who did not progress or die were censored at the last evaluable radiograph. If a patient had no evaluable postbaseline radiograph and did not die, then the patient was censored at day 1.